Guangzhou, China– August , 2024 – Inc. “The EC approval of BAT2206 is anothersignificant accomplishment for Bio-Thera as it marks Bio-Thera’s third EC approvedproduct” said Shengfeng Li, CEO at Bio-Thera. “Bio-Thera is committed toexpanding access fo...
View DetailsBio-TheraSolutions, a commercial-stage biopharmaceutical companydeveloping a pipeline of innovative therapies and biosimilars hassigned an exclusive License and Commercialisation Agreement with WorldMedicine, Türkiye'spharmaceutical export champion, ...
Guangzhou, China – Bio-Thera Solutions, Ltd. today announced thepublication of the Phase Iclinical study results for BAT4406F, an ADCC-enhanced fully humanized anti-CD20monoclonal antibody in Chinese patients with neuromyelitis optica spectrumdisorde...
Guangzhou, China, December 24, 2024 - Bio-TheraSolutions Inc.(688177:SH),a commercial-stage biopharmaceutical company developing a pipeline ofinnovative therapies and a pipeline of biosimilars, today announced the companyhas partnered with Tabuk Phar...
